J&J’s $5.8 Billion Talc Settlement, Who Is Covered as Another Trial Opens in Massachusetts? and How To Check Your Claim

Johnson & Johnson’s proposed settlement of ovarian cancer talc claims is worth at least $5.8 billion, according to plaintiffs’ lead negotiation counsel. J&J’s own SEC filing describes a $5.5 billion commitment. As of October 20, 2026, there is no verified public claim form and no universal public enrollment deadline for people who have not already filed a talc claim. The program is a private resolution for existing claims, and represented claimants are directed to their lawyers.

Official links: J&J’s July 27, 2026 SEC filing is at https://www.sec.gov/Archives/edgar/data/200406/000020040626000155/jnj-20260727.htm. Plaintiffs’ counsel’s announcement is at https://www.seegerweiss.com/news/plaintiffs-reach-uncapped-global-settlement-with-jj-company-to-pay-minimum-of-5-8-billion-to-resolve-talc-litigation/. Program materials name the administrator’s site as talcclaimsresolutionprogram.com, which we could not independently verify, so confirm it with your attorney before entering any personal information.

Separate case: Another talc trial reportedly began October 19 in Massachusetts, Hani Haddad, M.D., v. Johnson & Johnson, et al. It is a mesothelioma case, not an ovarian cancer case, and the ovarian settlement does not automatically resolve it.

Quick Facts: J&J Talc Settlement

Detail	Current information
Company	Johnson & Johnson
Amount announced by plaintiffs’ counsel	Minimum $5,800,000,000, uncapped
Amount in J&J’s SEC filing	$5,500,000,000 commitment
What it covers	Existing ovarian cancer talc claims (not future claims, not mesothelioma)
Claims covered	About 76,000 per J&J; about 70,000 plaintiffs per plaintiffs’ counsel
Participation condition	Participation by lead plaintiff firms representing at least 95% of remaining claims, among other conditions
Program name and administrator (per program materials)	Talc Claims Resolution Program, administered by Archer Systems, LLC
Official program site (reported, verify)	talcclaimsresolutionprogram.com
Payment structure	Individual awards using a tiered grid
First payments	No more than $3 billion in 2027 (per J&J)
Further payments	None before 2028 (per J&J)
Participation deadline	Program summary materials report September 1, 2026 for opt-in and release through participating firms, with registration 30 days later. Not independently verified
Public claim form	None verified
Federal litigation	In re Johnson & Johnson Talcum Powder Products Marketing, Sales Practices and Products Liability Litigation, MDL No. 2738 (D.N.J.)
New trial	Haddad v. Johnson & Johnson, et al., Middlesex Superior Court (Mass.), Case No. 2081CV02285
Did J&J admit liability?	No. J&J says its talc is safe and the claims lack merit
Who should act now	Anyone with an existing talc lawsuit should contact their attorney today

Is the J&J Talc Settlement Final?

Not yet, and it should not be treated as an approved consumer settlement. The Plaintiffs’ Negotiation Committee, Executive Committee and Steering Committee publicly supported the deal on July 28, 2026. J&J’s July 27 announcement describes a proposal that depends on participation by lead plaintiff firms representing at least 95% of the remaining claims, plus other conditions. If the threshold is not met or the program is terminated, program materials say opt-ins and releases become void and claims are preserved. The public announcements do not show that every condition is satisfied or that every claimant has enrolled.

Why Do J&J and Plaintiffs’ Lawyers Report Different Amounts?

J&J: In its July 27, 2026 SEC filing, J&J described a $5.5 billion commitment to resolve the remaining ovarian cancer litigation, with payments of no more than $3 billion in 2027 and nothing more due before 2028.

Plaintiffs’ counsel: On July 28, 2026, Seeger Weiss announced an uncapped settlement with a $5.8 billion minimum, using a tiered grid. Attorney Chris Seeger has said total payouts could exceed $7 billion.

The materials reviewed do not explain the gap. Attribute each figure to its source and do not treat $5.8 billion as confirmed in J&J’s filing. A guaranteed minimum with no cap also means the total is not fixed in advance.

Who May Qualify?

The deal is for existing, pending ovarian cancer claims in the MDL and related state cases. Using Johnson’s Baby Powder does not automatically qualify anyone. Program summary materials (not independently verified) describe these requirements:

• U.S. resident or citizen with a lawsuit filed on or before July 22, 2026 that is still pending, or an unfiled claim whose statute of limitations was still open at the relevant date.
• Sworn proof of consistent post-puberty perineal use of J&J talc products for at least four consecutive years.
• A first diagnosis at least 10 years after that use began.
• A qualifying epithelial cancer of the ovaries, fallopian tubes or peritoneum, in a subtype listed on the grid.

Claims already settled, dismissed, withdrawn or terminated on or before July 22, 2026 are excluded. Mesothelioma claims are on a separate track. Future claims are not covered. People newly diagnosed, or who have not filed, should not assume they can join and should get advice on state time limits.

How Are Awards Calculated?

Program materials describe a three-step grid, with amounts shown before attorneys’ fees, common-benefit assessments, costs and liens:

1. Base value by age at diagnosis (or recurrence or death) and cancer stage, reported as roughly $5,207 to $416,563.
2. Injury-type adjustment: for example, serous or poorly differentiated epithelial cancer at 100%, endometrioid at 90%, clear cell at 70%, with some subtypes lower.
3. Medical risk-factor discount for items such as family history or genetic predisposition, applying only the single largest discount.

The administrator makes the first determination. Claimants and J&J each get 30 days to object, and unresolved disputes go to a neutral special master whose decision is reported as final. These numbers are from program summaries, so ask your lawyer for the actual grid and your projected figure.

How To Check Your Eligibility and Participate

There is no public claim form, so the process runs through lawyers.

1. Contact your attorney if you already have a talc lawsuit. Ask whether your firm is participating and whether you already signed an opt-in and release.
2. Confirm the disease. The ovarian program does not automatically include mesothelioma or other diseases.
3. Ask for your deadlines in writing. Program materials report September 1, 2026 for the opt-in and release and 30 days later for registration items such as a stipulation of dismissal, but counsel’s public statement gave no universal date. Confirm yours.
4. Gather records: diagnosis and pathology reports, treatment history and product-use history. The administrator will tell your firm what is required.
5. Review before signing. Ask for the offered amount, fees, costs and liens, what will be released, and what happens to your lawsuit.
6. Object on time if you disagree with your proposed award (within 30 days of the determination).

If you were not represented or missed a firm deadline, speak to a talc attorney right away. You may still have limited options depending on your state’s time limit and the program rules.

Is There a Deadline To File a Claim?

There is no universal public deadline for people who have not filed. For represented claimants, deadlines run through their firms, and program summaries report a September 1, 2026 opt-in date that may already have passed. People who did not participate generally keep the right to litigate, but they face the specific-causation hurdles described below and the ordinary statute of limitations, which can expire regardless of this settlement.

Is This a Class Action? Are There Opt-Out or Objection Notices?

No. The materials describe a private resolution program, not a Rule 23 class settlement, so there is no class notice, opt-out letter or fairness hearing. Cases are individual lawsuits consolidated for pretrial purposes in an MDL under 28 U.S.C. § 1407 or pending in state courts. The practical choice is whether to opt in and sign a release or keep litigating. Funds are expected to be held in a qualified settlement fund (a tax-regulated escrow under Treasury Regulation § 1.468B-1), with the administrator also handling liens.

Why Did the Federal Court Order Matter?

On July 22, 2026, the MDL court ordered plaintiffs to show cause why remaining ovarian cancer cases should not be dismissed for failure to establish specific causation, meaning that talc caused each plaintiff’s own cancer rather than a general association. It involved about 69,000 claims and followed rulings on plaintiffs’ experts in two bellwether cases. It was not an automatic dismissal of every case, but it created a major risk for plaintiffs, and J&J announced the settlement five days later. Expert testimony in federal court must satisfy Federal Rule of Evidence 702, which was amended in December 2023 to emphasize the judge’s gatekeeping role.

What Happened to J&J’s Earlier Bankruptcy Attempts?

Prior to this agreement, Johnson & Johnson repeatedly attempted to resolve its talc liability through corporate bankruptcy filings. In 2023, courts dismissed bankruptcy filings by J&J subsidiary LTL Management after the Third Circuit ruled the entity was not in financial distress. Later, J&J subsidiary Red River Talc LLC submitted a $8 billion to $9 billion prepackaged reorganization plan in the U.S. Bankruptcy Court for the Southern District of Texas. However, in March 2025, U.S. Bankruptcy Judge Christopher Lopez rejected the plan and dismissed the Chapter 11 case due to voting and solicitation irregularities. Following these dismissals, ovarian cancer claims returned to the civil tort system, rendering older reports describing a “pending $8 billion Red River bankruptcy settlement” out of date.

The New Massachusetts Trial: Haddad v. Johnson & Johnson

A talc trial was listed as beginning October 19, 2026 in Middlesex Superior Court. The plaintiff is Hani Haddad, M.D., individually and as personal representative of the estate of Winifred Haddad. The case was filed September 22, 2020 (Case No. 2081CV02285) and alleges that exposure to asbestos-containing cosmetic talc, including Johnson’s Baby Powder, caused her mesothelioma.

Both sides are litigating expert evidence on asbestos testing, exposure and causation. Allegations in filings are not findings. The trial start comes from a public trial calendar, and no verdict was verified as of October 20, 2026. J&J said in July that it had settled about 95% of filed mesothelioma suits, and the Haddad case is a reminder that the ovarian settlement does not end all talc litigation. For a related look at other proceedings, see Pennsylvania J&J Talc Trial: What Internal Documents Reveal About Asbestos Concealment 2026.

What Laws and Rules Apply?

1. Multidistrict litigation: 28 U.S.C. § 1407

Related federal cases are transferred to one judge for pretrial proceedings. Plaintiffs keep their own individual claims, and cases return to their home courts if not resolved.

2. Product liability and failure-to-warn law

Claims are brought under state law, commonly strict liability (see Restatement (Second) of Torts § 402A), negligence, failure to warn and breach of warranty. The plaintiff must prove both general causation (talc can cause the disease) and specific causation (it did here).

3. Expert admissibility: Federal Rule of Evidence 702 and Daubert

Federal courts screen expert opinions for reliability. Many state courts apply similar or different standards. These gatekeeping rulings drove the July 22 order.

4. Aggregate settlements and lawyer ethics: ABA Model Rule 1.8(g)

In most states, a lawyer settling multiple clients’ claims together needs each client’s informed written consent, with disclosure of all participants’ claims and the amounts. Settlement programs can also require a firm to withdraw from non-participating clients where the ethics rules allow. Ask your lawyer how these rules apply to you.

5. Statutes of limitations

Time limits vary by state and often depend on when you knew or should have known the disease was linked to the product. In Massachusetts, wrongful death and many tort claims generally have a three-year period (M.G.L. c. 229, § 2; c. 260, § 2A). In an ovarian program that tolls limits only as its documents provide, do not assume more time than your lawyer confirms.

6. Liens: Medicare Secondary Payer Act and others

Medicare (42 U.S.C. § 1395y(b)(2)), Medicaid, ERISA plans and private insurers may have liens that must be paid from a settlement. The program uses a lien resolution administrator, and payments are expected only after liens are resolved.

7. Taxes: I.R.C. § 104(a)(2)

Damages received on account of personal physical injuries or physical sickness are generally excluded from federal gross income, but interest and punitive amounts can be taxable. Ask a tax advisor about your situation.

8. Bankruptcy channeling injunctions: 11 U.S.C. § 524(g)

Section 524(g) lets an asbestos-related debtor channel present and future claims to a trust if 75% of voting claimants approve and other requirements are met. It governed J&J’s earlier bankruptcy attempts, not the current private program.

What To Do If You Used J&J Talc and Have Not Filed

1. Do not assume you are covered. The ovarian program is for existing claims, and the deal does not create a public compensation fund.
2. Speak with a product-liability attorney promptly about your state’s limitations period.
3. Keep records: diagnosis and pathology reports, treatment records and any proof of product use.
4. Be cautious of unsolicited “settlement claim” websites and calls. Verify any administrator through your own lawyer or J&J’s SEC filing.

Key Dates

Date	Event
September 22, 2020	Haddad case filed in Massachusetts
2023	LTL Management bankruptcy filings dismissed
March 2025	Red River Talc bankruptcy plan rejected (as reported)
July 22, 2026	MDL court orders plaintiffs to show cause on specific causation; cutoff for filed claims under the program
July 27, 2026	J&J announces $5.5 billion commitment (SEC filing)
July 28, 2026	Plaintiffs’ counsel announces $5.8 billion minimum, uncapped
September 1, 2026	Reported opt-in and release deadline (program materials; unverified)
About October 1, 2026	Reported registration deadline (30 days later)
October 19, 2026	Haddad trial listed to begin
2027	First payments, no more than $3 billion
2028 or later	Further payments

Frequently Asked Questions

Is the J&J $5.8 billion talc settlement final?

Not confirmed. Plaintiffs’ committees support it, but it depends on a 95% participation condition and other terms. J&J’s filing says $5.5 billion, and plaintiffs’ counsel says a $5.8 billion minimum.

Is there a public claim form?

No verified public claim form. Represented claimants should contact their attorneys.

What is the deadline to join?

No universal public deadline was verified. Program materials report September 1, 2026 for opt-ins through participating firms. Confirm with your lawyer.

Who qualifies?

People with existing ovarian cancer claims that meet the program criteria. Product use alone is not enough.

Does it cover mesothelioma?

No. Mesothelioma is on a separate track.

Does it cover future claims?

No. It covers existing ovarian cancer claims only.

How much could I get?

It depends on the grid: age, stage, subtype and risk discounts. Program materials report base values from about $5,207 to $416,563 before adjustments, fees and liens. Your lawyer can calculate your figure.

Is this a class action?

No. It is a private program built on individual lawsuits.

What if I do not participate?

You can usually keep litigating, but you face causation challenges and time limits.

When will payments begin?

J&J says no more than $3 billion in 2027 and nothing more before 2028, subject to the terms.

Does the Haddad trial affect the ovarian settlement?

No. It is a state-court mesothelioma case with its own evidence and law.

Did J&J admit its talc causes cancer?

No. J&J denies liability and maintains its talc is safe.

Bottom Line

J&J’s proposed ovarian talc settlement is large, at $5.5 billion in J&J’s filing and at least $5.8 billion in plaintiffs’ announcement, but it is a private program for existing claims, conditioned on 95% participation, with no public claim form. Anyone with a talc lawsuit should confirm their status, deadlines, grid value, fees and release terms with their attorney now. Anyone without a filed claim should get legal advice on time limits instead of waiting. The Massachusetts mesothelioma trial is a separate matter.

Sources

1. Johnson & Johnson, SEC Form 8-K and Exhibit 99.1, July 27, 2026: https://www.sec.gov/Archives/edgar/data/200406/000020040626000155/jnj-20260727.htm
2. Seeger Weiss LLP, plaintiffs’ announcement, July 28, 2026: https://www.seegerweiss.com/news/plaintiffs-reach-uncapped-global-settlement-with-jj-company-to-pay-minimum-of-5-8-billion-to-resolve-talc-litigation/
3. Talc Claims Resolution Program, claimant program summary and administrator materials (Archer Systems, LLC): talcclaimsresolutionprogram.com
4. U.S. District Court, District of New Jersey, MDL No. 3:16-md-02738: https://www.njd.uscourts.gov/johnson-johnson-talcum-powder-litigation
5. Haddad v. Johnson & Johnson, et al., Middlesex Superior Court, Case No. 2081CV02285 (public docket filings): https://trellis.law/doc/292769035/response-to-defendant-s-motion-in-limine-to-preclude-opinions-dr-steven-haber-request-a-daubert-lanigan-hearing-filed-by-applies-to-hani-haddad-m-d-individually-personal-rep-estate-winifred-haddad-plaintiff
6. Courtroom View Network, public trial calendar: https://www.cvn.com/
7. Expert Institute, J&J’s $5.5 billion talc settlement proposal: https://www.expertinstitute.com/resources/insights/jnj-55b-talc-settlement/
8. Legal Examiner, J&J’s $5.5 billion talc settlement has a catch: https://www.legalexaminer.com/all/legal/j-js-5-5-billion-talc-settlement-has-a-catch-95-of-plaintiffs-must-say-yes/
9. 28 U.S.C. § 1407; 11 U.S.C. § 524(g); 42 U.S.C. § 1395y(b)(2); 26 U.S.C. § 104(a)(2): https://uscode.house.gov
10. Federal Rule of Evidence 702; ABA Model Rule of Professional Conduct 1.8(g); M.G.L. c. 229, § 2 and c. 260, § 2A: https://malegislature.gov

This article is for informational purposes only and is not legal advice. Settlement terms, participation conditions and deadlines may change and are governed by the program documents. AllAboutLawyer.com is a legal information website, not a law firm. Contact your attorney for claim-specific guidance.